Drug Channel Updates
Timely updates on drug shortages, launches, recalls, and more.
Top shortages
Colesevelam Hcl Tab 625mg 180s Quality review causing delay.
Morphine Cn 20mg/ml 30ml OSYN Increased demand/quotas.
Oxycod/Apap Tab 325mg 100s Quotas.
SodPot/Mag Sulf Sl 2x177ml Manufacturing delays causing shortages.
Drug Launches
The latest insights on the drug market.
Recent Launches
Byetta (exenatide injection) is a $45 million brand product and it launched April 7. Only the 10mcg/.04ml strength launched and the 5mcg/.02ml strength is anticipated to launch sometime next month. Amneal is the source vendor.
Anoro Ellipta (umeclidinium bromide; vilanterol trifenate) is a $1.1 billion market and launched April 14. Prasco is our source vendor. It’s anticipated there will be no additional vendors at launch time.
Upcoming Launches
Aptiom (eslicarbazepine acetate) is a $375 million market that’s anticipated to launch early to mid-May.
Arnuity Ellipta (fluticasone furoate) is a $334 million market and is anticipated to launch in late August. Prasco will be the source vendor.
Brilinta (ticagrelor) is a $1.3 billion market and is expected to launch sometime in May. The 60mg will have only one entrant but the 90mg will have multiple entrants. Might want to watch inventory on this high-volume item.
Complera (emtricitabine; rilpivirine; tenofovir) is a $107 million market and is expected to launch soon.
Fycompa tablets (perampanel) is a $244 million market and is projected to launch sometime in September. No additional info is available.
Jynarque (tolvaptan) is a $1.1 billion market. Expected to launch soon. This is a specialty item so will be exempt from rebates.
Osymia (phetermine hydrochloride topiramate) is a $51 million market, with launch imminent. Teva will be the source vendor.
Premarin tabs launch has been delayed until at least June. Vendors are awaiting final approval and will probably launch all strengths at the same time due to the delay.
Ravicti (glycerol phenlbutyrate) is a $469 million market scheduled to launch around July 1. This is a specialty item with one vendor to start.
Rytary (carbidopa levodopa) is a $337 million market. It’s expected to launch in late July or August. Currently, only one vendor is expected to enter the market.
Sandostatin LAR 20mg (octreotide acetate) is a $664 million market scheduled to launch around mid-July. No further information is available.
Saxenda (liraglutide recombinant) is a $217 million market and is now anticipated to launch sometime in September. Teva has been authorized to supply but is having operational delays.
Tasigna (nilotimib hydrochloride monohydrate) is a $1.2 billion market scheduled to launch around the first of June.
Day 181
Betimol (timolol) is a less than $10 market and will be available to others in June. The current source vendor is Somerset.
Mesnex (mesna) is a $6 million market. Available in July. The current source vendor is Ingenus.
Motegrity (prucalopride succinate) is a $161 million market. It will be available in June. The current source vendor is ANI.
Namzaric 14mg-10mg & 28mg-10mg (donepezil/memantine) is a $70 million market and will be available to others in July. The current source vendor is Amneal.
Stenda (avanafil) is less than $10 million market and will be available to others in May. The current source vendor is Camber.
Recalls
The most recent recall information with return forms.
Amneal Pharmaceuticals LLC
Company Name: Amneal Pharmaceuticals LLC
Product Description: Ropivacaine Hydrochloride Injection, USP, 500mg/100mL IV bag
Recall Reason: Product may contain an inert fiber identified as polypropylene fibers from the IV bag